Benign prostatic hyperplasia
ICD-10 N40 · ICD-11 GA90
Next-line protocol

BPH with Moderate-to-Severe Predominant Storage LUTS: When Medical Therapy Has Not Achieved Adequate IPSS Improvement

Some patients with benign prostatic hyperplasia (BPH) present with moderate to severe predominant storage lower urinary tract symptoms (LUTS). When an initial course of medical therapy targeting those symptoms does not produce a sufficient reduction in symptom burden, a defined next-line protocol is indicated.

The Clinical Scenario

This protocol addresses BPH patients with moderate to severe predominant storage LUTS. Anticholinergic agents — used alone or in combination with an alpha blocker — and beta-3-agonists combined with an alpha blocker are recognised medical options for this symptom pattern in the preceding treatment line.

Failure Condition Triggering This Protocol

The prior line employs anticholinergic agents (solifenacin, tolterodine, fesoterodine, or oxybutynin) — alone or combined with an alpha blocker — or mirabegron in combination with an alpha blocker.

Escalation criterion: When this medical therapy fails to achieve a decrease of more than 3 points in the IPSS from baseline at 4–12 weeks, the current next-line protocol is applied.

Next-Line Approach

Following confirmed failure of medical therapy, the next-line protocol considers surgical intervention. The choice of procedure is determined by individual patient factors and prostate characteristics — multiple surgical approaches are defined, each suited to specific anatomical profiles.

The complete structured regimen — specifying the full set of surgical options and the criteria that determine the appropriate procedure for each patient — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003698

  • Anticholinergic agents, alone or in combination with an alpha blocker, may be offered as a treatment option to patients with moderate to severe predominant storage LUTS.
  • Beta-3-agonists in combination with an alpha blocker may be offered as a treatment option to patients with moderate to severe predominate storage LUTS.
  • TURP should be offered as a treatment option for patients with LUTS/BPH.
  • PVP should be offered as an option using 120W or 180W platforms for the treatment of LUTS/BPH.
  • Holmium laser enucleation of the prostate (HoLEP) or thulium laser enucleation of the prostate (ThuLEP) should be considered as an option, depending on the clinician's expertise with these techniques, as prostate size-independent options for the treatment of LUTS/BPH.
  • Open, laparoscopic, or robotic assisted prostatectomy should be considered as treatment options by clinicians, depending on their expertise with these techniques, only in patients with large to very large prostates.
View source ↗